Drug Type Small molecule drug |
Synonyms CX-5461 |
Target |
Action modulators, inhibitors |
Mechanism G4 modulators(G-Quadruplex modulators), TOP2B inhibitors(DNA topoisomerase II beta inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
RegulationFast Track (United States) |
Molecular FormulaC27H27N7O2S |
InChIKeyXGPBJCHFROADCK-UHFFFAOYSA-N |
CAS Registry1138549-36-6 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Burkitt Lymphoma | Phase 2 | - | 19 Sep 2025 | |
High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements | Phase 2 | - | 19 Sep 2025 | |
Adenocarcinoma of large intestine | Phase 2 | - | 12 Sep 2025 | |
Metastatic Colorectal Carcinoma | Phase 2 | - | 12 Sep 2025 | |
Microsatellite Stable Colorectal Carcinoma | Phase 2 | - | 12 Sep 2025 | |
Unresectable Colorectal Carcinoma | Phase 2 | - | 12 Sep 2025 | |
Hematologic Neoplasms | Phase 2 | Australia | - | 12 Jan 2021 |
Ovarian Cancer | Phase 2 | United States | 10 Jan 2021 | |
Breast Cancer | Phase 2 | Canada | 07 Sep 2018 | |
HER2 Positive Solid Tumors | Phase 1 | - | 09 Dec 2025 |
Phase 1 | 28 | CX-5461 250 mg/m2 | xgsjgkthmb(suavwrwbmi) = 2 palmar-plantar erythrodysesthesia, 2 photosensitivity, 1 ocular photosensitivity; no grade 4 AE gdtzsckwsv (okzweesgya ) View more | Positive | 14 Sep 2024 | ||
CX-5461 325 mg/m2 | |||||||
Phase 1 | 40 | sxteatitmp(jnfiqyosym) = 475 mg/m2 days 1, 8 and 15 every 4 weeks adgyksbwxp (xmdqtnukuy ) | Positive | 24 Jun 2022 | |||
Phase 1 | DNA Repair-Deficiency Disorders BRCA1/2 deficient | HR-deficient tumors | 40 | CX-5461 | tulhyxugep(awaspptmql) = eidfeeddwt smkoaytwkg (zqyucafnir ) | Positive | 15 Feb 2020 | |
Phase 1 | 13 | pybofiqylr(dyubjwvthk) = Other adverse events (AEs) have been mild cytopenias related to underlying disease cmgxlltbrj (erkxhwkcwk ) View more | - | 20 May 2015 |